Archive: Company News
BellaSeno Demonstrates Superior Biomechanical Properties of its 3-D Printed, Resorbable Scaffolds for Bone Reconstruction
— Data presented at the 24th EFFORT Congress in Vienna (Austria)
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced comparative data on the biomechanical properties of different polycaprolactone/hydroxylapatite bone reconstruction scaffolds. The results, presented at the 24th EFORT Congress in Vienna, Austria, demonstrate that BellaSeno’s established manufacturing process results in bone scaffolds that can withstand higher loads and longer stress cycles than those produced by competing technologies.
MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
— FDA grants orphan drug designation for MetrioPharm’s lead compound MP1032 for the treatment of Duchenne muscular dystrophy (DMD)
— DMD is a designated orphan disease in both Europe and the U.S.
— MetrioPharm’s development objectives: better tolerability of existing therapies and improved efficacy in long-term treatment of DMD patients
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy.
selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
— Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity
— Dosing of MAD stage has been initiated; first results expected for late summer 2023
selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments of T-cell mediated autoimmune diseases, today announced excellent initial safety results of the single ascending dose (SAD) stage in the Phase 1b trial of its drug candidate si-544 in atopic dermatitis patients. si-544 is a selectivity-optimized peptide blocking the ion channel Kv1.3.
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
– First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia. Read more…